Clinical Trial
doi: 10.1016/s0002-9149(99)00421-x.
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial
Affiliations
- PMID: 10498145
- DOI: 10.1016/s0002-9149(99)00421-x
Item in Clipboard
Clinical Trial
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. RAPPORT investigators. ReoPro And Primary PTCA Organization and Randomized Trial
Am J Cardiol.
.
Abstract
We investigated the effect of platelet fibrinogen receptor blockade on infarct size after primary angioplasty. Abciximab significantly reduced the time-to-peak creatine kinase without affecting enzymatic infarct size, suggesting a beneficial effect on the pattern and speed of reperfusion.
Similar articles
-
Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.J Am Coll Cardiol. 1999 May;33(6):1528-32. doi: 10.1016/s0735-1097(99)00038-8. J Am Coll Cardiol. 1999. PMID: 10334418
-
Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction.Am J Cardiol. 2000 Aug 1;86(3):269-74. doi: 10.1016/s0002-9149(00)00912-7. Am J Cardiol. 2000. PMID: 10922431
-
[Gastrointestinal bleeding in a patient with acute myocardial infarction treated with primary coronary angioplasty and abciximab (ReoPro) administration].Kardiol Pol. 2006 Mar;64(3):334-6; discussion 337-8. Kardiol Pol. 2006. PMID: 16583343 Polish. No abstract available.
-
Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7. Atherosclerosis. 2012. PMID: 22483166 Review.
-
Abciximab: a review and update for clinicians.Expert Rev Cardiovasc Ther. 2008 Jun;6(5):609-18. doi: 10.1586/14779072.6.5.609. Expert Rev Cardiovasc Ther. 2008. PMID: 18510478 Review.
Cited by
-
Acute myocardial infarction: thrombolysis.Heart. 2000 Jan;83(1):122-6. doi: 10.1136/heart.83.1.122. Heart. 2000. PMID: 10618353 Free PMC article. Review. No abstract available.
-
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.Cochrane Database Syst Rev. 2013 Nov 8;2013(11):CD002130. doi: 10.1002/14651858.CD002130.pub4. Cochrane Database Syst Rev. 2013. PMID: 24203004 Free PMC article.
-
Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration during percutaneous coronary intervention for acute myocardial infarction.J Thromb Thrombolysis. 2006 Jun;21(3):229-34. doi: 10.1007/s11239-006-5706-2. J Thromb Thrombolysis. 2006. PMID: 16683214
-
Antiplatelet agents for chronic kidney disease.Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4. Cochrane Database Syst Rev. 2022. PMID: 35224730 Free PMC article.
-
Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.Clin Cardiol. 2000 Nov;23 Suppl 6(Suppl 6):VI-18-22. doi: 10.1002/clc.4960231106. Clin Cardiol. 2000. PMID: 11129682 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
